HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

pateamine A

a 19-membered macrolide; structure in first source; inhibits eukaryotic translation initiation

Networked: 7 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Pelletier, Jerry: 2 articles (06/2012 - 12/2009)
2.	Fürstner, Alois: 1 article (01/2018)
3.	Zhuo, Chun-Xiang: 1 article (01/2018)
4.	Désaubry, Laurent: 1 article (01/2017)
5.	Malka-Mahieu, Hélène: 1 article (01/2017)
6.	Newman, Michelle: 1 article (01/2017)
7.	Robert, Caroline: 1 article (01/2017)
8.	Vagner, Stéphan: 1 article (01/2017)
9.	Cammas, Anne: 1 article (06/2012)
10.	Di Marco, Sergio: 1 article (06/2012)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2009 - "We report here that des-methyl, des-amino pateamine A (DMDA-PatA), a structurally simplified analogue of the marine natural product pateamine A, has potent antiproliferative activity against a wide variety of human cancer cell lines while showing relatively low cytotoxicity against nonproliferating, quiescent human fibroblasts. " 02/17/2006 - "A recent publication revealing that the cytotoxic marine natural product pateamine A targets eukaryotic initiation factor eIF4A continues a story with lessons for both chemists and biologists, that is, the significance of natural products, the importance of synthetic organic chemistry, the small molecule regulation of eukaryotic translation machinery, and possibly a new approach to cancer chemotherapy." 12/01/2009 - "Several inhibitors have been characterized over the last 5 years that target the ribosome recruitment phase (eukaryotic initiation factor [eIF]4E [antisense oligonucleotides and 4EGI-1] or eIF4A [pateamine A, hippuristanol and silvestrol]), some of which demonstrate activity in preclinical cancer models. "
2.	Carcinogenesis 01/01/2017 - "Here, we review the contribution of the eIF4F complex to tumorigenesis, with a focus on its role in chemoresistance as well as the promising use of new small-molecule inhibitors of the complex, including flavaglines/rocaglates, hippuristanol, and pateamine A. "
3.	Necrosis 06/12/2012 - "Here we show that a low dose of pateamine A, an inhibitor of translation initiation, prevents muscle wasting caused by the cytokines interferon γ and tumour necrosis factor α or by C26-adenocarcinoma tumours. "
4.	Melanoma (Melanoma, Malignant) 01/01/2018 - "The marine natural product pateamine A (1) and its somewhat simplified designer analogue DMDA-Pat A (2) (DMDA = desmethyl-desamino) are potently cytotoxic compounds; most notably, 2 had previously been found to exhibit a promising differential in vivo activity in xenograft melanoma models, even though the ubiquitous eukaryotic initiation factor 4A (eIF4A) constitutes its primary biological target. "
5.	Infections 02/01/2011 - "Despite a rapid shutoff of host translation during CrPV infection, several hallmark SG markers such as the Drosophila TIA-1 and G3BP (RasGAP-SH3-binding protein) homologs, Rox8 and Rin, respectively, do not aggregate in CrPV-infected cells, even when challenged with potent SG inducers such as heat shock, oxidative stress, and pateamine A treatment. "

Related Drugs and Biologics

1.	Peptide Initiation Factors (Initiation Factor)
2.	hippuristanol
3.	Eukaryotic Initiation Factor-4A (Eukaryotic Initiation Factor 4A)
4.	Eukaryotic Initiation Factor-4F (EIF4F)
5.	Eukaryotic Initiation Factor-4E
6.	Antisense Oligonucleotides
7.	Cytokines
8.	Interferons
9.	des-amino pateamine A des-methyl
10.	silvestrol

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)